A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Ohio State University Comprehensive Cancer Center
Merck Sharp & Dohme LLC
University Medical Center Groningen
Eisai Inc.
Sheba Medical Center
Ohio State University Comprehensive Cancer Center